Circulating estradiol defines the tumor phenotype in menopausal breast cancer patients
- PMID: 19647960
- DOI: 10.1016/j.maturitas.2009.07.001
Circulating estradiol defines the tumor phenotype in menopausal breast cancer patients
Abstract
Objective: To correlate circulating hormone levels with the clinical and biological features of the tumors in menopausal breast cancer patients.
Design: Circulating hormone levels were measured in 161 previously untreated menopausal breast cancer patients within 72 h of their planned surgery. The obtained hormone levels were correlated with tumor size, histological and nuclear grade, histological score, axillary nodal status, DNA-ploidy and Ki67-, c-erb-B2-, p53, Bax-, VEGF- and Nup88-expression.
Results: The only statistically significant correlations found between circulating hormone levels and all tested variables were an inverse one between estradiol and the expression of the apoptosis-associated Bax gene (p=0.009), and again an inverse correlation between estradiol and the expression of c-erb-B2 (p=0.04). When comparing hormone levels with each other, a significant correlation between estradiol and progesterone (p<0.0001), an inverse one between estradiol and FSH (p=0.04) and a direct one between LH and prolactin (p=0.001) were found.
Conclusion: Higher circulating estradiol levels in postmenopausal breast cancer patients are associated with molecular features usually defining a biologically less aggressive tumor phenotype.
Comment in
-
Circulating estradiol and tumor phenotype in postmenopausal breast cancer patients.Maturitas. 2009 Nov 20;64(3):196; author reply 197. doi: 10.1016/j.maturitas.2009.08.010. Epub 2009 Sep 16. Maturitas. 2009. PMID: 19762179 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
